16+ min ago (1402+ words) The stock has underperformed the S&P 500 over the past year, weighed down by softer oil prices and company'specific operational and legal issues, yet it still offers a dividend yield around 4.6% and an aggressive share'repurchase program " a combination that keeps Chevron firmly on the radar of income and value'oriented investors. [2] Below is a detailed, news'driven look at Chevron's stock price, latest headlines (28"30 November 2025), fundamental backdrop and near'term forecast before the U.S. market opens on Monday, December 1, 2025. Because U.S. markets were closed over the weekend, the reference point for Monday's open is Friday, November 28, 2025: On a longer horizon: Earlier in the week, CVX had traded in the red for seven straight sessions, sliding to around $148.58 on Tuesday, before recovering into Friday's close " a pattern that underscores how fragile sentiment has been around the stock. [8] Chevron's near'term outlook is tightly linked to crude: The…...

21+ min ago (1221+ words) As Wall Street heads into the first trading day of December 2025, Caterpillar Inc. (NYSE: CAT) is sitting near record highs, riding a powerful mix of AI'driven energy demand, robust earnings " and mounting questions about tariffs and valuation. Below is a comprehensive look at Caterpillar's stock price, the key news and analysis from November 28"30, 2025, and what it all could mean for CAT shares before the market opens on Monday, December 1, 2025. U.S. markets were open for a shortened post'Thanksgiving session on Friday, November 28, 2025. Caterpillar finished that day essentially at all'time highs: In headline terms: Caterpillar enters December priced as a premium industrial, trading just below its 52'week high after a huge 2025 rally. Most of the news from Nov. 28"30 is still reacting to Caterpillar's strong Q3 2025 earnings release on October 29 and the forward guidance management gave at that time. From Caterpillar's own release and subsequent…...

26+ min ago (1183+ words) As U.S. markets prepare to reopen on Monday, December 1, 2025, Pfizer Inc. (NYSE: PFE) heads into the new week trading in a tight range but surrounded by a flurry of fresh analysis, institutional activity and strategic news from November 2830. At the close on Friday, November 28, 2025, Pfizer shares finished around $25.74, giving the drugmaker a market capitalization of roughly $146 billion. [1] With U.S. equity markets shut over the weekend, that closing print is the key reference point for investors going into Monday's session. In this pre'open update, we break down Pfizer's latest stock price action, key news from November 2830, 2025, and what current analyst forecasts imply for PFE over the next 12 months " plus the main risks that could sway the stock in December. From a performance standpoint, Pfizer's shares have lagged the Dow Jones Industrial Average: Despite that underperformance, a Barchart analysis on November 28 notes that PFE…...

38+ min ago (818+ words) Updated November 30, 2025 Pfizer stock is in the middle of a big reset. The COVID windfall is fading, but a massive obesity-drug acquisition, a landmark bladder'cancer approval and a high dividend yield are reshaping the story investors see in PFE. As of the last trading session on Friday, November 28, Pfizer Inc. (NYSE: PFE) closed at$25.74per share. That gives the company a market capitalization of roughly$146 billion. [1] Pfizer's share price is still down sharply from its 20212022 COVID peak above $50, so even after a modest 2025 rebound, the stock trades at roughlyhalfthose prior highs. On November 4, 2025, Pfizer reportedQ3 2025results: Analysts have generally characterized the quarter assolid: EPS beat expectations, revenue came in roughly in line, and the guidance uplift is driven partly by cost cuts and a lower tax rate rather than top'line acceleration. [11] A major new macro driver for Pfizer " and the whole U.S. pharma sector…...

39+ min ago (1276+ words) As Wall Street heads into the first trading day of December, GE Vernova Inc. (NYSE: GEV) is set to open Monday, December 1, 2025, near $600 a share after a powerful late'November run fueled by strong earnings momentum, new international wind contracts and a flood of fresh research coverage. [1] Between November 28 and November 30, financial media, quant platforms and analysts pushed out a concentrated burst of updates on GE Vernova's outlook. Here's how that three'day news window is shaping expectations before the bell. Trading volume on Friday came in around 1.0 million shares, well below the roughly 3 million'share average, suggesting that the latest move higher has not yet attracted the kind of heavy turnover seen earlier in the year. [5] On standard valuation metrics, GE Vernova is expensive: Zacks gives GE Vernova an "F" Value Style Score, explicitly flagging the stock as trading at a premium…...

40+ min ago (919+ words) As of the close of U.S. trading on'Friday, 28 November 2025, Nebius Group N.V.: So, Nebius stock today is a classic'hyper'growth AI story: huge run'up, big swings, and valuations that assume the company can keep executing almost perfectly. Nebius is a Dutch technology company building'full'stack cloud infrastructure for AI, not a consumer'internet or ad business.' [6] Nebius emerged out of a complex restructuring of'Yandex N.V., with the AI infrastructure business carved out into a new Western'focused vehicle. That history partly explains why different data vendors disagree on earnings and margins'the accounting is still settling as the "old Yandex" fades from the numbers.' TechStock+1 In'September 2025, Nebius announced a'five'year deal with Microsoft'valued at about'$17.4 billion, with options that could lift the total to'$19.4 billion.' [11] A widely cited 24/7 Wall St. piece grouped Nebius with IREN and Cipher Mining as three companies attacking the'bright line bottlenecks'of AI: power and data'center…...

40+ min ago (747+ words) Merck & Co. (NYSE: MRK) is ending November 2025 on a strong note. A flurry of regulatory wins for cancer drug Keytruda, positive mid'stage data for heart drug Winrevair, and fresh deal'making have pushed the share price close to its 52'week high and reignited debate about the stock's upside as it heads toward the Keytruda patent cliff later this decade. Below is a detailed, news'driven look at Merck's stock price, the latest company developments, and what Wall Street and various forecasting models are projecting from here, as of30 November 2025. As of the close onFriday, 28 November 2025(the last trading day before November 30): The biggest story in November has been thesharp rally: MRK traded in the mid'$80s at the start of the month and has surged into the mid'$100s as a cluster of positive headlines hit in oncology and cardiovascular medicine. Historical data show the…...

44+ min ago (1075+ words) Opendoor Technologies (NASDAQ: OPEN) has gone from penny'stock territory to one of 2025s wildest meme'stock comebacks. The company is tearing up its old playbook, refounding itself as an AI'first software business, and handing shareholders a special dividend of tradable warrants " all while its core home'flipping operation remains unprofitable and analysts warn of steep downside. Heres a full breakdown of Opendoors stock price, latest news, AI strategy, warrant dividend, and Wall Street forecasts as of'November 30, 2025. As of the latest close on'Friday, November 28, 2025, Opendoor shares: According to MarketBeat and Yahoo Finance data, Opendoors stock has delivered a'year'to'date return of about 380%+, dramatically outpacing the S&P 500. [2] From a'52'week low around $0.51 per share in June 2025'to a'2025 high near $10.87, the stock has been a more'than'20'bagger off the bottom for perfectly timed traders. [3] That explosion has turned Opendoor into a'full'blown meme stock, with multiple…...

46+ min ago (1067+ words) As U.S. markets head into the Monday, December 1, 2025 open, Citigroup Inc. (NYSE: C) is coming off one of its strongest stretches in years. The stock finished Friday around $103.60, just below its 52week high of $105.59 and up roughly 4548% yeartodate, significantly ahead of the S&P 500s gain. [1] Between November 2830, a burst of fresh research, institutional filings and valuation work has reshaped the conversation around Citi heading into the new week. Heres a detailed premarket look at where things stand, what changed over the last three days, and what traders and longterm investors will likely be watching today. Technical sentiment is broadly bullish: Citi has been trading above both its 50day and 200day moving averages since spring, confirming a strong uptrend into yearend. [7] On November 28, Zacks highlighted that Citigroups 1.07% gain to $103.60 outpaced the S&P 500s 0.54% rise that day and has also beaten both the broader market and the…...

47+ min ago (1036+ words) AbbVie Inc. (NYSE: ABBV) heads into Monday's December 1, 2025 open sitting near the middle of its recent trading range, with a lot of fresh information for investors to digest from November 2830. From November 28 to 30, three themes dominated the AbbVie story: Technical dashboards show AbbVie consolidating after a big year. TipRanks data puts the share price near $227.66, close to its 20" and 50"day moving averages (around $226$231) and well above its 100" and 200"day averages around the low $200s, painting a picture of a longer"term uptrend taking a breather. [8] On a purely technical basis, the stock screens as a "Hold: short"term momentum is neutral (RSI near 50), but longer"term moving averages still flash "buy signals, consistent with a stock that has rallied hard and is now pausing rather than breaking down. [9] Fundamentally, AbbVie's Q3 2025 numbers remain the anchor for most valuation work: Those metrics sit…...